Fallopian tube carcinoma--a review.

Ann Acad Med Singap

Department of Obstetrics and Gynaecology, King's College Hospital, Denmark Hill, London, United Kingdom.

Published: September 1998

Although a common site of metastases, primary fallopian tube carcinoma comprises only 0.3% of all gynaecological malignancies. Presenting symptoms are variable and non-specific, with preoperative diagnosis rarely entertained. The FIGO system assigns nearly two-thirds of patients to stage I or II and is based on surgical staging criteria similar to those for ovarian cancer. Likewise, management is based on that for ovarian cancer-radical debulking followed by platinum-based combination chemotherapy. Five-year survival for patients with disease confined to the tube at diagnosis (stage I) is only about 60% and only 10% of patients with advanced disease will be cured.

Download full-text PDF

Source

Publication Analysis

Top Keywords

fallopian tube
8
tube carcinoma--a
4
carcinoma--a review
4
review common
4
common site
4
site metastases
4
metastases primary
4
primary fallopian
4
tube carcinoma
4
carcinoma comprises
4

Similar Publications

Background: Gadolinium-iodine mixed contrast agents can significantly improve the visualization of the fallopian tubes in magnetic resonance hysterosalpingography (MR-HSG). However, the mixing ratio of gadolinium-iodine contrast agents has not yet been standardized.

Purpose: To explore the optimal mixing ratio of gadolinium-iodine contrast agents suitable for MR-HSG.

View Article and Find Full Text PDF

Background: There is indication that the fallopian tubes might be involved in ovarian cancer pathogenesis and their removal reduces cancer risk. Hence, bilateral salpingectomy during hysterectomy or sterilization, so called opportunistic salpingectomy (OS), is gaining wide acceptance as a preventive strategy. Recently, it was discussed whether implementation of OS at other gynecologic surgery, e.

View Article and Find Full Text PDF

Sperm navigation through the complex microarchitecture of the fallopian tube is essential for successful fertilization. Spatiotemporal structural alteration due to folded epithelium or muscle contractions in the fallopian tube changes the geometry of the sperm pathways. The role of structural complexity in sperm navigational patterns has been investigated for single sperm cells but has not been fully addressed at the population level.

View Article and Find Full Text PDF

Fallopian Tube Papilloma: A Systematic Review of Case Reports.

Niger Med J

January 2025

Department of Obstetrics and Gynecology, Army Hospital, Chandigarh, Punjab, India.

Fallopian tube papilloma (FTP) is one of the benign lesions of the oviduct and is a rare proliferative epithelial lesion. Low incidence and underreporting of the disease limit our knowledge of these lesions. These lesions cause a diagnostic dilemma and need to be differentiated from several other conditions of the fallopian tubes both benign and malignant.

View Article and Find Full Text PDF

Role of Leucine-Rich Repeat-Containing G-Protein-Coupled Receptors 4-6 (LGR4-6) in the Ovary and Other Female Reproductive Organs: A Literature Review.

Cell Transplant

January 2025

Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien.

Leucine-rich repeat-containing G-protein-coupled receptors regulate stem cell activity and tissue homeostasis within female reproductive organs, primarily through their interaction with the Wnt/β-catenin signaling pathway. LGR4-6 are increasingly recognized for their roles in organ development, regeneration, and cancer. This review aims to provide a comprehensive overview of the roles of LGR4-6 in female reproductive organs, highlighting their significance in normal physiology and disease states, specifically in the context of ovarian cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!